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Abstract 
Aims/hypothesis CUG-binding protein 1 (CUGBP1) is a multifunctional RNA-binding 
protein that regulates RNA processing at several stages including translation, 
deadenylation and alternative splicing, as well as RNA stability. Recent studies indicate 
that CUGBP1 may play a role in metabolic disorders. Our objective was to examine its 
role on endocrine pancreas function through gain- and loss-of-function experiments and 
to further decipher the underlying molecular mechanisms. 
Methods A mouse model in which type 2 diabetes was induced by a high-fat diet (HFD; 
60% energy from fat) and mice on a standard chow diet (10% energy from fat) were 
compared. Pancreas-specific CUGBP1 overexpression and knockdown mice were 
generated. Different lengths of the phosphodiesterase subtype 3B (PDE3B) 3′ 
untranslated region (UTR) were cloned for luciferase reporter analysis. Purified CUGBP1 
protein was used for gel shift experiments. 
Results CUGBP1 is present in rodent islets and in beta cell lines; it is overexpressed in 
the islets of diabetic mice. Compared with control mice, the plasma insulin level after a 
glucose load was significantly lower and glucose clearance was greatly delayed in mice 
with pancreas-specific CUGBP1 overexpression; the opposite results were obtained upon 
pancreas-specific CUGBP1 knockdown. Glucose- and glucagon-like peptide1 (GLP-1)-
stimulated insulin secretion was significantly attenuated in mouse islets upon CUGBP1 
overexpression. This was associated with a strong decrease in intracellular cAMP levels, 
pointing to a potential role for cAMP PDEs. CUGBP1 overexpression had no effect on 
the mRNA levels of PDE1A, 1C, 2A, 3A, 4A, 4B, 4D, 7A and 8B subtypes, but resulted in 
increased PDE3B expression. CUGBP1 was found to directly bind to a specific 
ATTTGTT sequence residing in the 3′ UTR of PDE3B and stabilised PDE3B mRNA. In 
the presence of the PDE3 inhibitor cilostamide, glucose- and GLP-1-stimulated insulin 
secretion was no longer reduced by CUGBP1 overexpression. Similar to CUGBP1, 
PDE3B was overexpressed in the islets of diabetic mice. 
Conclusions/interpretation We conclude that CUGBP1 is a critical regulator of insulin 
secretion via activating PDE3B. Repressing this protein might provide a potential 
strategy for treating type 2 diabetes. 
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Abbreviations 
CUGBP1 CUG-binding protein 1 
GLP-1 Glucagon-like peptide 1 
GSIS Glucose-stimulated insulin secretion 
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KD Knockdown 
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PDE Phosphodiesterase 
RIP-Chip RNA-binding protein immunoprecipitation profiling 
SpCas9 Streptococcus pyogenes clustered, regularly interspaced, short palindromic 
repeat (CRISPR)-associated endonuclease 9 
UTR Untranslated region 
Introduction 
Insulin is secreted by pancreatic beta cells of the islets of Langerhans; it is the only 
hormone capable of lowering plasma glucose levels [1, 2]. Glucose-stimulated insulin 
secretion (GSIS) occurs via glucose metabolism in beta cells [3]. Glucose metabolism 
leads to an increased cytosolic ATP/ADP ratio and the closure of ATP-sensitive K+ 
channels in the plasma membrane. The resulting depolarisation of the plasma membrane 
triggers Ca2+ influx through voltage-dependent Ca2+ channels, leading to an increased 
cytosolic Ca2+ concentration which is required for insulin granule exocytosis. However, 
GSIS also occurs via metabolic coupling factors other than ATP [3]. In addition, insulin 
secretion can be mediated by various hormones, including leptin, growth hormone and 
glucagon-like peptide 1 (GLP-1) [2]. 
Accumulating evidence indicates that cAMP is an integral component of GSIS [4, 5]. 
The intracellular level of cAMP is tightly controlled by its synthesis through adenylyl 
cyclases and its degradation through phosphodiesterases (PDEs). PDEs have been 
classified into 11 families according to their amino acid sequence, catalytic 
characteristics, substrate preference and regulatory properties [6]. Several PDE subtypes 
and isoforms, including PDE1 [7], PDE3B [8, 9], PDE4 [7] and PDE8B [7, 10], are 
known to mediate insulin secretion by pancreatic islets and/or beta cells. Through a 
feedback mechanism, insulin can reduce intracellular cAMP levels via activation of PDEs 
either by phosphorylation [11, 12] or in the longer term by regulating their protein 
levels[13, 14]. 
CUG-binding protein 1 (CUGBP1) is a member of the CUGBP and embryonic lethal 
abnormal vision-like factor (CELF) family of RNA-binding proteins. It preferentially 
binds to GU-rich elements located in the 5′ and 3′ untranslated regions (UTRs), as well as 
in mRNA coding regions [15, 16]. The association of CUGBP1 with its mRNA targets 
influences their alternative splicing, translation and turnover [17]. CUGBP1 is 
ubiquitously expressed and plays a critical role in various physiological and pathological 
cellular processes, including skeletal muscle differentiation and atrophy [18–21], cell 
proliferation [22], heart development and disease [23–25], and tumour growth [26]. 
Recently, several studies indicate that CUGBP1 may be involved in metabolic disorders. 
CUGBP1 has been reported to mediate alternative splicing of the insulin receptor [27] 
and to contribute to insulin resistance [28]. Verma et al showed that CUGBP1 is 
upregulated in the hearts of diabetic mice [29]. A recent genome-wide association study 
analysis suggested that genetic variation at the CUGBP1 locus is associated with obesity 
[30]. 
Here, we show that CUGBP1 is present in rodent islets and beta cells lines and is 
overexpressed in the islets of diabetic mice. We thus examined its potential role in 
endocrine pancreas function through gain- and loss-of-function experiments and further 
deciphered the underlying molecular mechanisms. 
 
Methods 
For detailed methods, please see the electronic supplementary material (ESM) methods. 
 
Animals All animal protocols described in this study were performed according to the 
Guidance for the Care and Use of Laboratory Animals published by the US National 
Institutes of Health (NIH Publication No. 85-23, revised 1996) and approved by the 
Institute of Biophysics Committee on Animal Care. Mice were housed under a 12 h:12 h 
light:dark cycle at a constant temperature (22–24°C), and had free access to water and 
food. Eight-week-old wild-type and db/db mice were kindly provided by W. Jin from the 
Institute of Zoology, Beijing, China. Adult male C57BL/6 mice were purchased from 
Beijing Vital River Laboratory Animal Technology (Beijing, China). As previously 
reported, seven-week-old mice were randomly divided into two groups [31]: one group 
received standard rodent chow (10% energy from fat; Beijing HFK Bioscience, Beijing, 
China) and the other group received a high-fat diet (HFD; 60% energy from fat; rodent 
diet D12492, Research Diets, New Brunswick, NJ, USA). Animals were fed a HFD or 
chow diet for 30 weeks. 
 
Reagents and plasmids Cilostamide was purchased from Tocris Bioscience (Bristol, 
UK). All other reagents were from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise 
stated. The pcDNA3.1-CUGBP1 plasmid was a generous gift from H. Lou, Case Western 
Reserve University, Cleveland, OH, USA. The pLenti-OC-IRES-BSD plasmid and 
lentiviral sgRNA vector were kindly provided by W. Wei,  Peking University, Beijing, 
China. The firefly and renilla luciferase vectors were provided by Y. Wu from Institute of 
Biophysics, Chinese Academy of Sciences, Beijing, China. The pcDNA3.1 and 
pDsRed2-N1 plasmids were obtained from Addgene (Cambridge, MA, USA). 
 
Adenovirus generation Adenoviruses were prepared using the AdEasy XL Adenoviral 
Vector System (Stratagene, La Jolla, CA, USA). Schematic diagrams are shown in ESM 
Fig. 1.  
 
IPGTTs GTTs were performed by i.p. injection of 1.5 g/kg glucose into mice after 
fasting for 16 h. Glucose levels were measured using an automatic glucometer (Accu-
Chek; Roche Diagnostics, Mannheim, Germany). In some experiments, the AUC for 
glucose during the IPGTT (120 min) was calculated with GraphPad Prism 6 (La Jolla, 
CA, USA). 
 
Insulin secretion and content analysis Islets were isolated and cultured as previously 
described [32]. Islets were infected by Ad-DsRed or Ad-DsRed-Cugbp1 and incubated 
for 48 h. Insulin secretion and total insulin content were then measured. 
 
Western blotting Western blotting was performed as previously described [33]. 
Briefly, protein samples from HeLa cells or mouse islets were resolved by SDS-PAGE 
and immunoblotted with anti-PDE3A, anti-PDE3B, anti-CUGBP1 or anti-β-actin 
antibody. 
 
Immunofluorescence analysis Immunofluorescence was used to determine the 
expression of CUGBP1 in mouse pancreases or MIN6 cells. 
 
Plasma insulin measurement Eight-week-old male mice were infected with Ad-
DsRed or Ad-DsRed-CUGBP1 (control mice vs CUGBP1 OE mice) or an adenovirus 
expressing the gene encoding clustered, regularly interspaced, short palindromic repeats 
(CRISPR)-associated endonuclease from Streptococcus pyogenes (SpCas9; Ad-SpCas9) 
plus Ad-GFP/Ad-SpCas9 plus Ad-SpGuide (control mice vs CUGBP1 KD mice) by 
direct injection into the pancreas, as previously published [34]. After infection, plasma 
insulin levels were measured. 
 
cAMP assay Islets were extracted in lysis buffer provided in the cAMP XP assay kit 
(no. 4339; Cell Signalling Technology, Danvers, MA, USA). Intracellular cAMP 
concentrations were determined and normalised to protein concentration, according to the 
manufacturer’s instructions. 
 
RNA isolation and PCR RNA was extracted from HeLa cells or mouse islets using the 
Trizol RNA purification system (Invitrogen, Carlsbad, CA, USA), and reverse transcribed 
into cDNA using M-MLV reverse transcriptase (Promega, Madison, WI, USA). PCR and 
quantitative qPCR were performed as previously reported [35]. 
 
RNA-binding protein immunoprecipitation RNA-binding protein 
immunoprecipitation (RIP-CHIP) was performed with HeLa cell lysates, as previously 
described [36]. 
 
Luciferase reporter assay Different lengths of the PDE3B 3′ UTR were amplified and 
cloned into the firefly vector. Sewing PCR was used to generate mutant PDE3B 3′ UTR 
sequences, as previously reported [37]. 
 
Gel shift assay CUGBP1 protein was purified as previously reported [15]. The RNA 
oligonucleotide (5′-AUUUGUU-3′) was synthesised by GenScript (Nanjing, China). 
 
PDE3B mRNA stability assay PDE3B mRNA stability assay was performed as 
previously reported [38]. 
 
Statistical analysis Significant differences were determined between two groups using 
the Student’s t test or among multiple groups using ANOVA. Data are shown as mean ± 
SEM, and statistical significance was set at p<0.05. 
 
Results 
CUGBP1 is overexpressed in the islets of diabetic mice To understand the function of 
CUGBP1, we first examined its expression in the whole murine pancreas. As shown in 
ESM Fig. 2a, we found that CUGBP1 was evenly distributed in the islets and exocrine 
areas. Western blotting showed that CUGBP1 was abundantly expressed in rodent islets 
and in two pancreatic beta cell lines (INS1 and MIN6), at similar levels as in the mouse 
extensor digitorum longus and soleus (ESM Fig. 2b). Immunostaining revealed that 
CUGBP1 was mainly located in the cytoplasm of MIN6 cells (ESM Fig. 2c). 
Two classic mouse models of type 2 diabetes (db/db and HFD-fed mice) were used 
to investigate whether type 2 diabetes modifies the expression of CUGBP1. The db/db 
mice had a higher body weight (p<0.001; Fig. 1a) and impaired glucose clearance 
compared with control mice (Fig. 1b). CUGBP1 protein was upregulated 2.2-fold in the 
islets of db/db mice compared with control mice (p<0.001; Fig. 1c). As shown in Fig. 1d, 
the average body weights of HFD-fed and chow-fed mice were 52.6±1.1 g and 36.4±1.2 
g (p<0.001), respectively. IPGTTs revealed that glucose tolerance was markedly impaired 
in HFD-fed mice compared with chow-fed mice (Fig. 1e). As for db/db mice, the level of 
CUGBP1 protein was also significantly higher in the islets of HFD-fed mice compared 
with chow-fed mice (p<0.05; Fig. 1f). Taken together, our results indicate that CUGBP1 
is overexpressed in the islets of diabetic mice. 
 
CUGBP1 is a negative regulator of insulin secretion Overexpression (OE) of Cugbp1 
in the islets of diabetic mice led us to speculate that CUGBP1 may play a role in insulin 
secretion. To test this hypothesis, we generated mice overexpressing pancreas-specific 
Cugbp1 by directly injecting Ad-DsRed-CUGBP1 into the mouse pancreas (ESM Fig. 
3a). Control mice were injected with Ad-DsRed. We observed DsRed throughout the 
pancreas, indicating that the exogenous protein (DsRed or DsRed-CUGBP1) was 
strongly expressed (ESM Fig. 3b). CUGBP1 was overexpressed by about 2.5-fold in the 
islets of CUGBP1 OE mice (ESM Fig. 3c). As shown in Fig. 2a, the fasting plasma 
insulin level was not significantly different between control and CUGBP1 OE mice. 
However, the glucose-stimulated plasma insulin level was significantly lower in 
CUGBP1 OE mice than in control mice (Fig. 2a). Therefore, CUGBP1 OE mice cleared 
glucose at a significantly slower rate compared with control mice (Fig. 2b). 
We further investigated the function of CUGBP1 by generating a mouse model with 
pancreas-specific CUGBP1 knockdown (KD) which was induced using SpCas9. As 
shown in ESM Fig. 4a, Ad-Sp-Cas9 and Ad-Sp-GuideGFP (1:1 ratio) were directly 
injected into the pancreas to disrupt the Cugbp1 gene (CUGBP1 KD mice). Control mice 
were injected with Ad-Sp-Cas9 and Ad-GFP (1:1 ratio). A T7 endonuclease I cleavage 
assay and genomic DNA sequencing revealed no evidence of mutagenesis in control 
mice, while CUGBP1 KD mice displayed mutations at multiple sites (ESM Fig. 4b,c). 
Western blot analysis demonstrated that CUGBP1 protein content was reduced by about 
50% in pancreatic islets (ESM Fig. 4d). Although the fasted plasma insulin level was only 
moderately enhanced, glucose-stimulated plasma insulin levels were significantly 
increased in CUGBP1 KD mice compared with control mice (Fig. 2c). IPGTT results 
showed that glucose clearance was faster in CUGBP1 KD mice than in control mice (Fig. 
2d). 
To test whether CUGBP1 is involved in in vitro insulin secretion, isolated islets were 
infected with Ad-DsRed-CUGBP1; control islets were infected with Ad-DsRed. Ad-
DsRed-CUGBP1 infection led to a 3.8-fold upregulation of CUGBP1 (ESM Fig. 5). As 
shown in Fig. 2e, secreted insulin levels were similar in control and CUGBP1 OE islets 
in the presence of 3.3 mmol/l glucose; however, upon 16.7 mmol/l glucose stimulation 
insulin levels in CUGBP1 OE islets were significantly lower than in control islets 
(p<0.05). GLP-1 is known to stimulate insulin secretion through binding to and activating 
the GLP-1 receptor, and thereby inducing cAMP production [39]. We therefore tested 
whether CUGBP1 has a role in GLP-1-induced insulin secretion. We found that GLP-1 
(10 nmol/l) stimulated insulin secretion from 13.9±0.7 to 50.9±8.1 ng/mg in control islets 
and from 11.7±0.8 to 27.3±0.8 ng/mg in CUGBP1 OE islets (Fig. 2f). Although basal 
insulin levels were similar in CUGBP1 OE islets and control islets (13.9 vs 11.7 ng/mg), 
GLP-1-stimulated insulin secretion was markedly decreased in CUGBP1 OE islets (50.9 
vs 27.3 ng/mg, p<0.05; Fig. 2f). However, the total insulin content (Fig. 2g) and Ins1 and 
Ins2 mRNA levels (Fig. 2h) were similar in control and CUGBP1 OE islets, suggesting 
that CUGBP1 has no effect on insulin production. 
 
cAMP, but not intracellular Ca2+, mediates CUGBP1 function We next investigated 
the mechanisms by which CUGBP1 negatively regulates insulin secretion. Given the 
importance of Ca2+ in GSIS and the fact that Ca2+ signalling can be modulated by 
CUGBP1 in the heart [25], we hypothesised that the intracellular Ca2+ concentration 
([Ca2+]i) might modulate CUGBP1-induced GSIS impairment. To test this, [Ca2+]i was 
recorded in isolated islets, as previously reported [40]. We found that glucose-induced 
Ca2+ release was similar in control and CUGBP1 OE islets (Fig. 3a,b), indicating that 
Ca2+ signalling is not involved in CUGBP1-mediated effects. 
cAMP is an important regulator of GSIS [4, 5, 41]. We therefore investigated 
whether the intracellular cAMP concentration ([cAMP]i) was modified upon CUGBP1 
OE. As seen in Fig. 3c, the [cAMP]i stimulated by 16.7 mmol/l glucose was 2.4±0.3 
nmol/mg in control islets but only 1.4±0.2 nmol/mg in CUGBP1 OE islets (n=4 groups, 
p<0.05), indicating that CUGBP1 decreases cAMP levels upon glucose stimulation. 
 
CUGBP1 induces PDE3B expression As PDEs are the only enzymes that specifically 
hydrolyse cAMP [6], we speculated that PDE activation might be responsible for the 
CUGBP1-dependent decrease in cAMP content. We therefore measured the mRNA levels 
of most PDE family genes under control and CUGBP1 OE conditions in HeLa cells and 
mouse islets. CUGBP1 OE had no effect on the mRNA levels of all PDE genes with the 
exception of PDE3B which was clearly induced (Fig. 3d,e and ESM Fig. 6). Owing to 
their lack of gene expression in HeLa cells and mouse islets, the effects of CUGBP1 on 
PDE4C, PDE10A and PDE11A mRNA levels were not determined. In isolated islets, 
CUGBP1 OE increased the Pde3b mRNA level by about twofold (Fig. 4a) and 
upregulated PDE3B protein by threefold (Fig. 4b). Consistent with this, PDE3B 
expression was markedly decreased in islets from CUGBP1 KD mice compared with 
control mice (Fig. 4c). Unlike for PDE3B, PDE3A protein level was not changed upon 
CUGBP1 OE (ESM Fig. 7). 
 
PDE3B inhibition rescues CUGBP1-mediated GSIS impairment So far, our results 
suggest that inhibition of GSIS by CUGBP1 is due to activation of PDE3B. The selective 
PDE3 inhibitor, cilostamide (10 µmol/l), was used to further examine this hypothesis. 
Both glucose- and GLP-1-stimulated insulin secretion were strongly reduced by 
CUGBP1 OE (Fig. 4d,e). We found that cilostamide markedly enhanced insulin secretion 
by both control and CUGBP1 OE islets, but abolished the inhibitory effects of CUGBP1 
(Fig. 4d). We also showed that GLP-1 induced insulin secretion was no longer reduced by 
CUGBP1 OE in the presence of cilostamide (Fig. 4e). These results confirm that PDE3B 
activation is involved in CUGBP1 inhibition of insulin secretion. 
Based on these results, we speculated that PDE3B should be overexpressed in the 
islets of diabetic mice. This was indeed the case: PDE3B protein expression was 
increased by 11-fold (p<0.01; Fig. 4f) and 2.5-fold (p<0.05; Fig. 4 g) in islets from db/db 
and HFD-fed mice, respectively. 
 
CUGBP1 directly binds to the PDE3B 3′ UTR and promotes mRNA stabilisation 
To gain insight into the molecular mechanisms underlying PDE3B activation by 
CUGBP1, we performed RIP-CHIP, luciferase reporter, gel shift and mRNA stability 
assays. RIP-CHIP experiments showed that PDE3B mRNA was enriched in the RNA 
population pulled down by CUGBP1 but not by control IgG, indicating that CUGBP1 
binds to PDE3B mRNA (Fig. 5a). We further demonstrated that most PDE mRNAs were 
not pulled down by CUGBP1; an exception was PDE4B mRNA (data not shown). As 
PDE4B expression was not affected by CUGBP1 OE (Fig. 3d), the interaction between 
the two proteins was not further investigated. A luciferase reporter assay was then 
conducted to determine whether CUGBP1 binds to the PDE3B 3′ UTR. As CUGBP1 
regulates the PDE3B level in both HeLa cells (Fig. 3d, ESM Fig. 6) and mouse islets 
(Fig. 4a–c), we reasoned that the mechanisms responsible for this regulation may be 
conserved. Thus, we aligned the 3′ UTRs of human, rat, and mouse PDE3B genes and 
found that about 1,000 bp were conserved among these species. We therefore chose 1,144 
bp of the human PDE3B 3′ UTR as the potential CUGBP1 target. As shown in Fig. 5b, 
luciferase activity was modestly increased in constructs containing the 1–1,144 and 1–
938 bp 3′ UTR sequences but not in constructs containing the 1–557 and 1–756 bp 
sequences. Moreover, luciferase activity was not significantly different between 
constructs containing the 1–1,144 and 1–938 bp sequences. These results indicate that the 
CUGBP1-interacting sequence is located in the region from 756 bp to 938 bp. Using a 
bioinformatics method (www.introni.it/splicing.html), two potential binding sites for 
CUGBP1 were found in this region: one is TTGTTGTTTTTACTCT, the other is 
ATTTGTT. We therefore constructed two luciferase reporters containing a mutated 1–938 
bp sequence in which either the TTGTTGTTTTTACTCT (mutant-1) or ATTTGTT 
(mutant-2) sequence was deleted. The luciferase activity of the mutant-1 reporter was still 
increased by CUGBP1, whereas that of mutant-2 was unchanged, suggesting that 
CUGBP1 binds to the ATTTGTT sequence. A gel shift assay further demonstrated that 
CUGBP1 can directly bind to the ATTTGTT sequence in a dose-dependent manner (Fig. 
5c). Finally, we found that the rate of PDE3B mRNA decay was much slower in 
CUGBP1 OE cells than in control cells, suggesting that CUGBP1 can stabilise PDE3B 
mRNA (Fig. 5d). 
 
Discussion 
In this study, we report that: (1) CUGBP1 is present in both rodent islets and beta cell 
lines, and is overexpressed in the islets of diabetic mice; (2) CUGBP1 acts as a negative 
regulator of insulin secretion upon glucose and GLP-1 stimulation; (3) the effects of 
CUGBP1 on insulin secretion are mediated by PDE3B activation; (4) CUGBP1 directly 
regulates PDE3B expression via binding to the ATTTGTT sequence within its 3′ UTR; 
and (5) PDE3B is overexpressed in the islets of diabetic mice. 
In vivo genome editing in adult animals is a topic of intense interest and has had a 
profound impact on both basic and translational research. Recently, SpCas9 has been 
proven to be a powerful tool for making precise genomic perturbations in vivo. It has 
been used in vivo to study the function of genes in the liver and brain [42, 43] and to cure 
metabolic and genetic diseases with animal models [44]. Here, we demonstrated that 
SpCas9 can be used to disrupt the genes in adult mouse islets. To our knowledge, this is 
the first report of the use of SpCas9 to edit genes in adult mouse islets in vivo. Moreover, 
we found that SpCas9-mediated Cugbp1 mutation had a strongly increased insulin 
secretion, reduced glucose homeostasis and significantly downregulated PDE3B 
expression, indicating that in vivo genome editing with SpCas9 is feasible in adult mouse 
islets. 
We have demonstrated for the first time that CUGBP1 is critical for controlling 
insulin secretion by pancreatic islets. Importantly, CUGBP1 is overexpressed in the islets 
of diabetic mice, and this presumably leads to insufficient insulin secretion. A previous 
study indicated that CUGBP1 contributes to insulin resistance in skeletal muscle [28]. 
Moreover, a recent genome-wide association study suggested that genetic variation at the 
CUGBP1 locus is associated with obesity [30], which is a major risk factor for the 
development of type 2 diabetes. Collectively, these results suggest that CUGBP1 may be 
an important regulator of type 2 diabetes. Thus, CUGBP1 inhibition might be a potential 
strategy for the treatment of type 2 diabetes. 
In a mechanistic analysis, we identified cAMP and PDE3B as the molecules are 
responsible for the effects of CUGBP1. Indeed, accumulating evidence indicates that 
intracellular cAMP is an important regulator of insulin secretion either dependent or 
independent of Ca2+ [4, 5, 41]. Although several PDE proteins regulate insulin secretion 
[7–10, 45], only PDE3B can be activated by CUGBP1. Actually, PDE3B OE results in 
reduced insulin secretion by islets and beta cells [9, 46, 47]; conversely, GSIS is 
enhanced in islets from Pde3b-null mice [8]. In addition, various hormones including 
IGF-1 [48] and leptin [49] regulate insulin secretion through phosphorylation of PDE3B. 
PDE3A and PDE3B are well known to be involved in different cellular processes and 
to participate in distinct diseases [6], but there is no specific inhibitor for each isoform. In 
this study, we found that the ATTTGTT sequence residing in the 3′ UTR of PDE3B is 
required to stabilise PDE3B mRNA. We are therefore now in the position to design 
specific molecular disruptors of PDE3B activation using a strategy similar to the one 
used to inhibit another RNA-binding protein, the Hu antigen R [50]. 
In summary, our data demonstrate that CUGBP1 is a critical regulator of insulin 
secretion via activation of PDE3B. As CUGBP1 is overexpressed in the islets of diabetic 
mice, its repression might provide a potential strategy for the treatment of type 2 diabetes. 
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 Fig. 1 CUGBP1 is overexpressed in the islets of diabetic mice. (a) Body weight and (b) 
IPGTTs of wild-type (WT) and db/db mice (8-week-old; n=4). Black circles, WT; white 
squares, db/db. (c) The CUGBP1 protein level was significantly elevated in islets isolated 
from db/db mice. (d) Body weight and (e) IPGTTs of chow- and HFD-fed mice (n=4–5). 
(f) The CUGBP1 protein level was significantly elevated in the islets isolated from HFD-
fed mice. Seven-week-old male mice were fed an HFD or chow diet for 30 weeks. Black 
circles, chow; white squares, HFD. Data are the mean ± SEM. *p<0.05, **p<0.01 and 
***p<0.001 vs control  
 
Fig. 2 CUGBP1 is a negative regulator of insulin secretion. (a) Plasma insulin levels 
and (b) IPGTTs for control and CUGBP1 OE mice (n=4–9). White bars/squares, control; 
black bars/squares, CUGBP1 OE. (c) Plasma insulin levels and (d) IPGTTs for control 
and CUGBP1 KD mice (n=4–10). White bars/squares, control; grey bars/squares, 
CUGBP1 KD. (e) Glucose (Glu)-stimulated and (f) GLP-1-stimulated insulin secretion 
and (g) total insulin content in control and CUGBP OE islets (n=4 groups). (h) Ins1 and 
Ins2 mRNA levels were measured in control and CUGBP OE islets (n=4 groups). (e–g) 
Each group contains 40–60 islets isolated from at least two mice. White bars, control; 
black bars, CUGBP1 OE. NS, not significant. Data are the mean ± SEM. *p<0.05, 
**p<0.01, and ***p<0.001 vs control 
 
Fig. 3 Effects of CUGBP1 on [Ca2+]i, [cAMP]i and PDE expression. (a) [Ca2+]i was 
recorded in control (grey line) and CUGBP1 OE (black line) islets. (b) Summary data 
show the amplitude of the [Ca2+]i response of control (white bar; n=12) and CUGBP1 OE 
(black bar; n=11) islets. [Ca2+]i is expressed as ratio F/F0 (F0 is the average fluorescence 
intensity in the presence of 3.3 mmol/l glucose). (c) Glucose-stimulated [cAMP]i was 
measured in control (white bar) and CUGBP1 OE (black bar) islets (n=4 groups). Each 
group contains about 100 islets isolated from three mice. (d, e) Representative RT-PCR 
shows the effects of CUGBP1 OE on the mRNA levels of various PDE family genes in 
(d) HeLa cells or (e) mouse islets. Data are the mean ± SEM. *p<0.05 vs control 
 
Fig. 4 PDE3B is activated by CUGBP1 and upregulated in the islets of diabetic mice. 
(a, b) PDE3B mRNA (a) and protein (b) levels were elevated in CUGBP1 OE islets 
(n=3–6 groups). Each group contains 40–60 islets isolated from at least two mice. White 
bars, control; black bars, CUGBP1 OE. (c) PDE3B protein was decreased in the islets 
isolated from CUGBP1 KD mice (n=4–6). White bars, control; grey bars, CUGBP1 KD. 
(d, e) Effect of 10 µmol/l cilostamide on glucose-stimulated (d) and GLP-1-stimulated 
(e) insulin secretion in control and CUGBP1 OE islets (n=4 groups). Each group contains 
40–60 islets isolated from at least two mice. White bars, control; black bars, CUGBP1 
OE. (f, g) PDE3B protein level was elevated in (f) db/db and (g) HFD-fed mice (n=4–5). 
White bars, control; black bars, db/db or HFD. Cil, cilostamide; CTL, control; Glu, 
glucose. Data are the mean ± SEM. *p<0.05 and **p<0.01 vs control. Exo-CUGBP1, 
exogenous CUGBP1; endo-CUGBP1, endogenous CUGBP1 
 
Fig. 5 CUGBP1 directly interacts with the PDE3B 3′ UTR and promotes mRNA 
stabilisation. (a) Representative PDE3B RT-PCR product after RIP-CHIP. (b) Luciferase 
activity of PDE3B 3′ UTR constructs. White bars, control; black bars, different PDE3B 3′ 
UTR constructs, as indicated. (c) PAGE shows that CUGBP1 interacts with the 5′- 
AUUUGUU -3′ sequence. (d) HeLa cells were treated with actinomycin D to inhibit gene 
transcription and the percentage PDE3B mRNA expression (relative to t=0) was 
quantified using RT-qPCR at the indicated time points (n=4). White squares, control; 
black squares: CUGBP1 OE. CUG, CUGBP1; IP, immunoprecipitation; Luc, luciferase. 
*p<0.05, **p<0.01 and ***p<0.001 vs control or as indicated. 





Electronic supplementary material (ESM) Methods 
Adenovirus Generation 
Adenoviruses were prepared according to the AdEasy™ XL Adenoviral Vector System 
(Stratagene, La Jolla, CA, USA). The DsRed, Cugbp1 and Cas9 genes were obtained 
from pDsRed2-N1, pcDNA3.1-CUGBP1 and pLenti-OC-IRES-BSD, respectively. The 
20-nucleotide (nt) target sequence (GAAGAGTGCCGGATATTGCG) was selected to 
precede a 5'-NGG protospacer-adjacent motif (PAM) sequence and cloned into the 
pLenti-sgRNA-Lib vector. Then, all the genes and 20-nt sequence were cloned into a 
shuttle vector. All constructs generated were sequence-verified. The resultant plasmids 
were linearized by digesting with restriction endonuclease Pme I and subsequently 
transformed into the competent AdEasier cells. After confirmation, the recombinant 
adenovirus plasmids were transfected into AD-293 cells by using LipofectamineTM 2000 
(Invitrogen, Carlsbad, CA, USA). Generally, the adenoviruses were generated within 14-
20 days. All the adenoviruses generated were purified by CsCl gradient ultracentrifuge 
method and their concentrations were determined. 
Islets Isolation and Culture 
Islets were isolated from adult male C57BL/6 mice by using collagenase P (Roche 
Molecular Biochemicals, Indianapolis, IN, USA). Single islet was handpicked under 
microscopic guidance and cultured overnight in RPMI 1640 medium (Invitrogen) 
supplemented with 10% FBS, 1 mmol/l sodium pyruvate, 50 μmol/l β-mercaptoethanol, 
100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C in a 5% CO2 and 95% air 
atmosphere.  
Insulin Secretion and Content Analysis 
Isolated islets were infected by an adenovirus encoding DsRed (Ad-DsRed: control) or an 
adenovirus encoding CUGBP1 coupled to a fluorescent protein DsRed (Ad-DsRed-
CUGBP1: CUGBP1 OE) for 48 h. After infection, the islets were washed with KRB 
solution [composition (mmol/l): NaCl 137, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, 
NaHCO3 25, (pH 7.4), 1% (weight/volume) BSA] and incubated in KRB solution 
containing 3.3 mM glucose at 37°C for 2 h. Then, the islets were stimulated by 16.7 
mmol/l glucose or 10 nmol/l GLP-1 (in 3.3 mmol/l glucose KRB solution) for 1 h. In 
some cases, 10 µmol/l Cil was added and maintained for another 1 h. Supernatants of 
each condition were harvested and frozen until assayed. Finally, islets were collected and 
dissolved in RAPI solution (P0013; Beyotime Biotechnology, Beijing, China). Protein 
concentrations were determined with a classic BCA method. Insulin levels were 
quantified by using a rat/mouse insulin ELISA kit (EZRMI-13K; Millipore, Billerica, 
MA, USA) and normalized to protein concentration. 
Western Blot Analysis 
In brief, samples were resolved by SDS-PAGE and immunoblotted with the following 
antibodies: anti-PDE3A IgG (sc-20792; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, 
USA), anti-PDE3B IgG (sc-20793; Santa Cruz Biotechnology), anti-CUGBP1 IgG (sc-
20003; Santa Cruz Biotechnology), and anti-β-actin IgG (sc-47778; Santa Cruz 
Biotechnology). 
Immunofluorescence 
Mouse pancreas was fixed with 4% paraformaldehyde, embedded in paraffin and section 
onto glass slides. Immunofluorescence was performed by using an anti-insulin antibody 
(3014; Cell Signaling Technology, Inc., Danvers, MA, USA). Visualization of staining 
was achieved by using Alexa Fluor 488-conjugated secondary antibodies (Invitrogen). 
Nuclei were stained with DAPI. Images were captured by using the 40x oil immersion 
objective of an inverted microscope (Leica Microsystems, Germany) connected to a 
software-controlled (Las AF, Leica) cooled charge coupled camera (Leica SP5 confocal 
microscope). 
Plasma Insulin Measurement 
Eight-week-old mice were treated with Ad-DsRed/Ad-DsRed-CUGBP1 (control mice vs. 
CUGBP1 OE mice) or Ad-SpCas9 + Ad-GFP/Ad-SpCas9 + Ad-SpGuide (control mice 
vs. CUGBP1 KD mice) by direct injection into the pancreas. Eight (control and CUGBP1 
OE) or fourteen days (control and CUGBP1 KD) after infection, mice were subjected to 
the measurement of plasma insulin level and the test of glucose tolerance. The mice were 
deprived of food for 16 h. For GSIS, the mice were intraperitoneally injected with 1.5 
g/kg glucose. Blood samples were obtained from the retroorbital sinus before and 15 min 
after the injection of glucose. Insulin levels were measured by using a rat/mouse insulin 
ELISA kit (EZRMI-13K; Millipore). 
RNA Isolation and PCR 
HeLa cells were transfected with pcDNA3.1 vector or pcDNA3.1-CUGBP1 by using 
LipofectamineTM 2000 (Invitrogen). After transfection, total RNA was extracted by the 
Trizol RNA purification system (Invitrogen). According to the manufacturer’s 
instructions (Promega Corp., Madison, WI, USA), cDNA was generated from mRNA (2 
µg) with the M-MLV reverse transcriptase. Standard PCR was carried out on the 
generated cDNA with the primers sequences shown in ESM Table 1. PCR products were 
run on a 1.7% agarose gel and visualized under ultraviolet (UV) light by using ethidium 
bromide staining. RT-qPCR was performed on a Corbett Rotor-Gene 6600 QPCR system 
machine with the TransScriptTM Green RT-qPCR SuperMix (Transgene Biotech, 
Beijing, China). The gene-specific primers of RT-qPCR were 5'tctgacaacacggccagttc3' 
(forward) and 5'agacaggcagccataactct3' (reverse) for human PDE3B; 
5'agagctacgagctgcctgac3' (forward) and 5'agcactgtgttggcgtacag3' (reverse) for human β-
ACTIN; 5'atcgcagcagtggtaagagg3' (forward) and 5'gccagcagacactggtacat3' (reverse) for 
mouse Pde3b; 5'ccacaagtggaacaactgga3' (forward) and 5'gtgcagcactgatccacaat3' 
(forward) for mouse Ins1; 5'ggagcgtggcttcttctaca3' (forward) and 
5'cagtgccaaggtctgaaggt3' (forward) for mouse Ins2; and 5'tgtgatggtgggaatgggtcag3' 
(forward) and 5'tttgatgtcacgcacgatttcc3' (reverse) for mouse β-actin. Amplifications were 
performed with a 10 min template denaturation step at 95°C, followed by three steps for 
35 cycles (denaturation at 95°C for 30 s, annealing at 60°C for 30 s, and extension at 
72°C for 30 s). All samples were amplified in triplicate and the mean was obtained for 
further calculations. The comparative 2-∆∆Ct method was used to analyze mRNA fold 
changes. Then the calculated 2-∆∆Ct was transformed into a percentage by using the 
control as 100% to show the mRNA expression difference. 
RNA-Binding Protein Immunoprecipitation (RIP-CHIP) 
In brief, cell lysates were prepared from HeLa cells (70% confluence) just before use. 
Normal mouse IgG (sc-2025; Santa Cruz Biotechnology) or CUGBP1 IgG (sc-20003; 
Santa Cruz Biotechnology) were incubated with a 10% slurry of Protein-A/G sepharose 
beads (sc-2003; Santa Cruz Biotechnology) in NT-2 buffer [composition (mmol/l): Tris 
50 pH 7.4, NaCl 150, MgCl2 1, 0.05% (volume/volume) Nonidet P-40] and agitated 
overnight at 4°C. After the washing, the beads were dissolved in NT-2 buffer. Cell lysates 
were added to the beads. After mixing, 10% of the content was taken out as input and the 
remaining was mixed gently for 3 h at room temperature. After incubation, all the beads 
were washed six times by cold NT-2 buffer and then incubated in proteinase K buffer at 
55°C for 30 min. RNA extraction and RT-PCR were performed with the following 
sequences: 5'-aggtttaacaatgaagggat-3' (forward) and 5'-gagggaaattaacagaaagatg-3' 
(reverse). PCR products were run on a 1.7% agarose gel and visualized under UV light by 
using the ethidium bromide staining. 
Luciferase Reporter Assay 
The different lengths 3'-untranslated region (3'-UTR) of PDE3B were amplified with the 
primers shown in ESM Table 2 and cloned into the firefly vector. HeLa cells were seeded 
on 24-well plates and transfected with 200 ng pcNDA3.1 vector or pcDNA3.1-CUGBP1 
vector, 20 ng firefly vector containing different lengths of PDE3B 3'-UTR, and 20 ng 
Renilla vector by LipofectamineTM 2000 (Invitrogen). HeLa cells were harvested 48 h 
post transfection and assayed for reporter gene activity with a Dual-Luciferase® Reporter 
Assay System (E1910; Promega). Sewing PCR was used to generate mutant PDE3B 3'-
UTR as previously reported. 
Gel Shift Assay 
The RNA oligonucleotide (5'-auuuguu-3') was synthesized by GenScript Co., Ltd. 
(Nanjing, China). After the blending of the RNA probe and the CUGBP1 protein in the 
binding buffer [composition (mmol/l): Tris-HCl 50 pH 8.0, NaCl 120], the mixtures were 
incubated for 20 min at room temperature. The protein-RNA complexes were separated 
from free RNA on a 6% polyacrylamide gel prepared and pre-electrophoresed in 0.5x 
TBE buffer [composition (mmol/l): Tris 44.5, boric acid 44.5, EDTA 1]. Electrophoresis 
was performed in 0.5x TBE buffer at 8 mA for 3 h. Bands were visualized under UV light 
with SYBR® Gold Nucleic Acid Gel Stain (Invitrogen). 
  
Legends for ESM figures 
ESM Fig. 1 Schematic overview of different adenoviral vectors. CMV: 
cytomegalovirus; GFP: green fluorescent protein; DsRed: red fluorescent protein from 
Discosoma coral; ITR: inverted terminal repeat; NLS: nuclear localization signal; PolyA: 
bovine growth hormone gene polyadenylation site; sgRNA: single guide RNA; SpCas9: 
clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated 
endonuclease (Cas)9 from Streptococcus pyogenes; U6: Pol III promoter. 
ESM Fig 2 (a) Representative immunofluorescence staining using antibodies against 
CUGBP1 (red), insulin (green) in mouse pancreas. (b) Western blot analysis of CUGBP1 
expression in rodent islets, INS1 cells, MIN6 cells, mouse extensor digitorum longus, and 
soleus. (c) Representative immunofluorescence staining using antibodies against 
CUGBP1 (red), insulin (green) in MIN6 cells. Nuclei were stained in blue with DAPI. 
Scale bars, 25 µm. 
ESM Fig. 3 Adenovirus-mediated overexpression of CUGBP1 in adult mouse 
pancreas in vivo. (a) A carton showing the strategy to overexpress the Cugbp1 gene in 
adult mouse pancreas in vivo. (b) Eight days after injection, mouse pancreas was taken 
out, fixed with 4% paraformaldehyde, embedded in paraffin and section onto glass slides. 
To monitor the distribution of adenovirus, DsRed protein was directly excited at 543 nm 
and the emission was collected around 583 nm. Meanwhile, the pancreatic islets were 
indicated by using insulin staining. The representative immunofluorescence images show 
that DsRed (control) and DsRed-CUGBP1 (CUGBP1 OE) were expressed thorough out 
the pancreas. Nuclei were stained blue with DAPI. Scale bars, 10 µm. (c) Western blot 
was performed to test the relative expression of CUGBP1 in the islets from mice treated 
by Ad-DsRed (N=4) or Ad-DsRed-CUGBP1 (N=4). Representative western blot and 
summary data analysis were shown. Data are shown as Mean ± SEM. 
ESM Fig. 4 Adenovirus-mediated knockdown of CUGBP1 in adult mouse pancreas 
in vivo. (a) A carton showing the strategy to disrupt the Cugbp1 gene in adult mouse 
pancreas in vivo by using the SpCas9 system. To monitor the distribution of adenovirus, 
GFP was directly excited at 488 nm and the emission was collected at 510 nm. Five days 
after injection, GFP images were captured. A representative GFP image suggests that 
most of the pancreas was infected by adenovirus. Scale bars, 1 mm. (b, c) Genomic DNA 
analysis. Five days after injection, pancreatic areas with the brightest GFP fluorescence 
(as indicated in GFP image with the white rectangle) from mice treated by Ad-SpCas9 + 
Ad-GFP or Ad-SpCas9 + Ad-SpGuide were chose to extract DNA by using DNeasy 
Blood & Tissue Kit (Qiagen, Hilden, Germany). Then, target sequences were amplified 
on the extracted DNA by PCR. The PCR products were used for either T7 endonuclease I 
(T7E1) cleavage assay (NEB, USA) or genomic DNA sequencing. The representative 
results of T7E1 cleavage assay (b) and genomic DNA sequencing (c) were shown. 
Deletion and mutation sites were indicated with gray and red, respectively. (d) To test the 
relative expression of CUGBP1, western blots were performed in the islets taken from 
mice treated by Ad-SpCas9 + Ad-GFP (N=4) or Ad-SpCas9 + Ad-SpGuide (N=6). 
Representative western blot and summary data analysis were shown. Data are shown as 
Mean ± SEM. 
ESM Fig. 5 To overexpress CUGBP1, isolated islets were infected by Ad-DsRed or Ad-
DsRed-CUGBP1 for 48 h. Representative western blot and summary data analysis were 
shown. CTL: control; OE: overexpression.  Data are shown as Mean ± SEM. 
ESM Fig. 6 (a) RT-qPCR result shows the effects of overexpression of CUGBP1 on 
PDE3B mRNA in HeLa cells. (b) Representative western blots and summary data show 
the effects of overexpression CUGBP1 on the protein levels of PDE3B in HeLa cells. 
White bars, control; black bars, CUGBP1 OE. CTL: control; OE: overexpression. Data 
are shown as Mean ± SEM. *p<0.05 with Student’s t test. 
ESM Fig.7 Representative western blots show the effects of overexpression CUGBP1 on 
the protein levels of PDE3A in HeLa cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ESM Table 1: Primer sequences used for the expression of different PDE families 
and subtypes. 
Target 
gene 
Forward primers 
(5'→3') 
Reverse primers 
(5'→3') 
Fragment 
size (bp) 
Cycle Annealing 
temperature 
PDE1A ccactttgtgatcggaagtc ttctgctgaatgatgtccacc 323 34 55 °C 
PDE2A cctcctgtgacctctctgacc tgaacttgtgggacaccttgg 294 34 55 °C 
PDE3A tcacagggccttaacttacac ggagcaagaattggtttgtcc 339 34 55 °C 
PDE3B cctcaggcagttttatacaatg tgcttcttcatctccctgctc 387 34 55 °C 
PDE3B 
PDE4A 
ctttgggattgggactta 
gtggagaagtctcaggtggg 
caccatattgcgagcct 
tggaacttgtcaggcaggg 
105 
212 
34 
34 
55 °C 
55 °C 
PDE4B tagaagataacaggaactgg gcaatgtctatgtcagtctc 247 34 58 °C 
PDE4D ggataatggaggagttcttcc cgattgtcctccaaagtgtcc 295 34 55 °C 
PDE7A gcctctgagtggattacagtttc cagtcgagtctgcggatgt 354 34 56 °C 
PDE8B tggatcttagccctcgcttt tgcacaaagtttgcttggag 209 34 56 °C 
GAPDH ggctctccagaacatcatccctgc gggtgtcgctgttgaagtcagagg 269 25 55 °C 
 
 
 
 
 
 
 
 
 
 
 ESM Table 2: Primer sequences used for the expression of 3'-UTR of human 
PDE3B. 
PDE3B 
3'-UTR 
Forward primers 
(5'→3') 
Reverse primers 
(5'→3') 
1-557 ccacaattgcgacagtttgagtaaaagaaaagtc ccgctcgagataaacctagctggcagaat 
1-756 ccacaattgcgacagtttgagtaaaagaaaagtc ccgctcgagtaaacctaaacagctttaaaattcag 
1-938 ccacaattgcgacagtttgagtaaaagaaaagtc ccgctcgagtttagggctcactatatttcttttt 
1-1144 ccacaattgcgacagtttgagtaaaagaaaagtc ccgctcgagccagttctttacttgttctcag 
M1-1 
M1-2 
M2-1 
M2-2 
ccacaattgcgacagtttgagtaaaagaaaagtc 
agctcaggattcgtatttttaa 
ccacaattgcgacagtttgagtaaaagaaaagtc 
agaagaaaaaaaatttgctgt 
aaaaatacgaatcctgagctttttgactaaagaataaatc 
ccgctcgagtttagggctcactatatttcttttt 
cagcaaattttttttcttctctgtgctgtgttcatattaa 
ccgctcgagtttagggctcactatatttcttttt 
 
 
 
 
 
 
 
 
 
 
 
 
 
 







